Conexeu Sciences (NASDAQ:CNXU) Upgraded to “Hold” at Zacks Research

Conexeu Sciences (NASDAQ:CNXU) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

CNXU has been the subject of a number of other reports. HC Wainwright initiated coverage on shares of Conexeu Sciences in a research note on Monday, June 22nd. They set a “buy” rating and a $20.00 target price for the company. Wall Street Zen upgraded Conexeu Sciences to a “hold” rating in a research note on Saturday, May 30th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Conexeu Sciences Price Performance

Shares of CNXU stock opened at $10.92 on Monday. Conexeu Sciences has a 52 week low of $9.60 and a 52 week high of $18.79.

Conexeu Sciences (NASDAQ:CNXU) last released its quarterly earnings data on Monday, June 15th. The company reported ($0.11) earnings per share for the quarter.

Insider Buying and Selling

In other Conexeu Sciences news, Director Lynn Sebastian Purcell bought 202,500 shares of Conexeu Sciences stock in a transaction on Thursday, June 18th. The stock was acquired at an average cost of $0.80 per share, with a total value of $162,000.00. Following the completion of the acquisition, the director owned 2,734,240 shares in the company, valued at approximately $2,187,392. This represents a 8.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

More Conexeu Sciences News

Here are the key news stories impacting Conexeu Sciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $20 price target, signaling confidence in Conexeu Sciences despite near-term losses. Conexeu Sciences Free Report
• Positive Sentiment: The firm’s longer-term estimates turn sharply positive, with projected EPS of $1.02 for FY2028, $1.70 for FY2029, and $2.52 for FY2030, suggesting potential future earnings growth. Conexeu Sciences Free Report
• Neutral Sentiment: HC Wainwright’s near-term forecasts remain negative, including estimated losses of ($0.40) per share for FY2026 and ($0.53) for FY2027, which keeps investors focused on execution rather than current profitability. Conexeu Sciences Free Report

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.